Pharma BD Deal Intelligence
GSK paid $213M for 10M Theravance shares at a 7.5% premium to the 5-day VWAP, lifting its stake to ~26.8% and signaling intent to deepen the respiratory…
C&EN coverage characterized the move as GSK consolidating economic interest in its long-running LABA collaboration ahead of regulatory filings, with limited…
Retrospective: Trelegy Ellipta (FF/UMEC/VI) emerged as the franchise jewel from the GSK-Theravance respiratory alliance, with Royalty Pharma paying $1.1B for…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK equity investment to acquire 10M Theravance shares at $21.2887 (7.5% premium to 5-day VWAP) for $212.9M, raising stake from 18.3% to ~26.8%. Reinforced respiratory alliance covering Relovair, UMEC/VI, and triple-combination products.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Theravance, Inc. (this deal) | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
| GlaxoSmithKline plc / Reliant Pharmaceuticals Inc. | 2007 | $1.6B | 47 |
← Browse all deals · How we score deals
More: 2012 deals · GlaxoSmithKline plc deals · Respiratory deals